CA2395738A1 - Acides nucleiques, proteines et anticorps - Google Patents
Acides nucleiques, proteines et anticorps Download PDFInfo
- Publication number
- CA2395738A1 CA2395738A1 CA002395738A CA2395738A CA2395738A1 CA 2395738 A1 CA2395738 A1 CA 2395738A1 CA 002395738 A CA002395738 A CA 002395738A CA 2395738 A CA2395738 A CA 2395738A CA 2395738 A1 CA2395738 A1 CA 2395738A1
- Authority
- CA
- Canada
- Prior art keywords
- polypeptide
- seq
- sequence
- polypeptides
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 147
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 132
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 100
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 100
- 108091005461 Nucleic proteins Proteins 0.000 title description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 639
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 620
- 229920001184 polypeptide Polymers 0.000 claims abstract description 615
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 399
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 399
- 239000002157 polynucleotide Substances 0.000 claims abstract description 398
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 225
- 238000000034 method Methods 0.000 claims abstract description 181
- 239000013598 vector Substances 0.000 claims abstract description 64
- 238000004519 manufacturing process Methods 0.000 claims abstract description 19
- 239000012634 fragment Substances 0.000 claims description 164
- 239000002299 complementary DNA Substances 0.000 claims description 141
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 138
- 125000003729 nucleotide group Chemical group 0.000 claims description 118
- 239000002773 nucleotide Substances 0.000 claims description 114
- 230000014509 gene expression Effects 0.000 claims description 52
- 150000001413 amino acids Chemical class 0.000 claims description 51
- 230000027455 binding Effects 0.000 claims description 50
- 238000012217 deletion Methods 0.000 claims description 32
- 230000037430 deletion Effects 0.000 claims description 32
- 230000000694 effects Effects 0.000 claims description 32
- 230000004071 biological effect Effects 0.000 claims description 31
- 239000000047 product Substances 0.000 claims description 18
- 230000035772 mutation Effects 0.000 claims description 5
- 239000012472 biological sample Substances 0.000 claims description 4
- 238000004166 bioassay Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims 8
- 239000006228 supernatant Substances 0.000 claims 2
- 241000282414 Homo sapiens Species 0.000 abstract description 82
- 239000000203 mixture Substances 0.000 abstract description 16
- 239000000556 agonist Substances 0.000 abstract description 10
- 238000012216 screening Methods 0.000 abstract description 10
- 238000002560 therapeutic procedure Methods 0.000 abstract description 9
- 239000005557 antagonist Substances 0.000 abstract description 8
- 238000010188 recombinant method Methods 0.000 abstract description 6
- 238000002405 diagnostic procedure Methods 0.000 abstract description 5
- 238000010189 synthetic method Methods 0.000 abstract description 5
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 144
- 235000018102 proteins Nutrition 0.000 description 137
- 235000001014 amino acid Nutrition 0.000 description 78
- 230000000295 complement effect Effects 0.000 description 77
- 229940024606 amino acid Drugs 0.000 description 56
- 108091028043 Nucleic acid sequence Proteins 0.000 description 54
- 239000000427 antigen Substances 0.000 description 45
- 108091007433 antigens Proteins 0.000 description 44
- 102000036639 antigens Human genes 0.000 description 44
- 108020004414 DNA Proteins 0.000 description 38
- 108020001507 fusion proteins Proteins 0.000 description 37
- 102000037865 fusion proteins Human genes 0.000 description 37
- 238000009396 hybridization Methods 0.000 description 37
- 102000005962 receptors Human genes 0.000 description 37
- 108020003175 receptors Proteins 0.000 description 37
- 210000001519 tissue Anatomy 0.000 description 37
- 206010033128 Ovarian cancer Diseases 0.000 description 36
- 206010061535 Ovarian neoplasm Diseases 0.000 description 36
- 229920001223 polyethylene glycol Polymers 0.000 description 35
- 239000002202 Polyethylene glycol Substances 0.000 description 33
- 238000006467 substitution reaction Methods 0.000 description 33
- 230000000890 antigenic effect Effects 0.000 description 31
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 28
- 210000003719 b-lymphocyte Anatomy 0.000 description 28
- 239000003446 ligand Substances 0.000 description 27
- 108060003951 Immunoglobulin Proteins 0.000 description 25
- 102000018358 immunoglobulin Human genes 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 125000000539 amino acid group Chemical group 0.000 description 24
- 239000002585 base Substances 0.000 description 24
- 238000000746 purification Methods 0.000 description 23
- 238000005516 engineering process Methods 0.000 description 22
- 230000005714 functional activity Effects 0.000 description 22
- 230000004048 modification Effects 0.000 description 22
- 238000012986 modification Methods 0.000 description 22
- 108091026890 Coding region Proteins 0.000 description 20
- 108700026244 Open Reading Frames Proteins 0.000 description 20
- 238000003556 assay Methods 0.000 description 20
- 239000013604 expression vector Substances 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 239000000523 sample Substances 0.000 description 19
- 230000002163 immunogen Effects 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 17
- 210000004899 c-terminal region Anatomy 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 125000005647 linker group Chemical group 0.000 description 17
- 239000000463 material Substances 0.000 description 17
- -1 A15 Proteins 0.000 description 16
- 238000003018 immunoassay Methods 0.000 description 16
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 15
- 210000004408 hybridoma Anatomy 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 13
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 13
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 13
- 230000002759 chromosomal effect Effects 0.000 description 13
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 241000588724 Escherichia coli Species 0.000 description 12
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 230000000903 blocking effect Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 239000003550 marker Substances 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 238000013519 translation Methods 0.000 description 12
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 11
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 11
- 238000012545 processing Methods 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 210000001550 testis Anatomy 0.000 description 11
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 230000004927 fusion Effects 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 210000004379 membrane Anatomy 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 241001529936 Murinae Species 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 210000001072 colon Anatomy 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 238000004590 computer program Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000005755 formation reaction Methods 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 8
- 108020004511 Recombinant DNA Proteins 0.000 description 8
- 210000001672 ovary Anatomy 0.000 description 8
- 210000002741 palatine tonsil Anatomy 0.000 description 8
- 210000002307 prostate Anatomy 0.000 description 8
- 102000008100 Human Serum Albumin Human genes 0.000 description 7
- 108091006905 Human Serum Albumin Proteins 0.000 description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 240000008042 Zea mays Species 0.000 description 7
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 7
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 230000003302 anti-idiotype Effects 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 235000005822 corn Nutrition 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 201000000050 myeloid neoplasm Diseases 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 6
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 6
- 241000235058 Komagataella pastoris Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 230000021736 acetylation Effects 0.000 description 6
- 238000006640 acetylation reaction Methods 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 238000002399 angioplasty Methods 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 208000029742 colonic neoplasm Diseases 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 230000013595 glycosylation Effects 0.000 description 6
- 238000006206 glycosylation reaction Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 229940072221 immunoglobulins Drugs 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 6
- 230000006320 pegylation Effects 0.000 description 6
- 238000002823 phage display Methods 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 230000001323 posttranslational effect Effects 0.000 description 6
- 230000000717 retained effect Effects 0.000 description 6
- 230000009466 transformation Effects 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 108010025188 Alcohol oxidase Proteins 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 5
- 102100027221 CD81 antigen Human genes 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 5
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 229960000723 ampicillin Drugs 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 235000020958 biotin Nutrition 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000007385 chemical modification Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 210000003527 eukaryotic cell Anatomy 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 208000008675 hereditary spastic paraplegia Diseases 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 5
- 238000001114 immunoprecipitation Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000002969 morbid Effects 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 101100230428 Caenorhabditis elegans hil-5 gene Proteins 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 101710154606 Hemagglutinin Proteins 0.000 description 4
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 102000003839 Human Proteins Human genes 0.000 description 4
- 108090000144 Human Proteins Proteins 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
- 108091006006 PEGylated Proteins Proteins 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 101710176177 Protein A56 Proteins 0.000 description 4
- 101710086015 RNA ligase Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 108091081024 Start codon Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 230000009435 amidation Effects 0.000 description 4
- 238000007112 amidation reaction Methods 0.000 description 4
- 230000002788 anti-peptide Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000008827 biological function Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000002738 chelating agent Substances 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 230000001268 conjugating effect Effects 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 231100000599 cytotoxic agent Toxicity 0.000 description 4
- 238000001212 derivatisation Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- 230000022244 formylation Effects 0.000 description 4
- 238000006170 formylation reaction Methods 0.000 description 4
- 238000002873 global sequence alignment Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 235000018977 lysine Nutrition 0.000 description 4
- 229960000485 methotrexate Drugs 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 238000011275 oncology therapy Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 230000004853 protein function Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 230000000284 resting effect Effects 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 238000002864 sequence alignment Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- 239000013638 trimer Substances 0.000 description 4
- 238000010798 ubiquitination Methods 0.000 description 4
- 230000034512 ubiquitination Effects 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 241000972773 Aulopiformes Species 0.000 description 3
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 108010092160 Dactinomycin Proteins 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000005720 Glutathione transferase Human genes 0.000 description 3
- 108010070675 Glutathione transferase Proteins 0.000 description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 3
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- 241000235648 Pichia Species 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 102400001051 Restin Human genes 0.000 description 3
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 238000007818 agglutination assay Methods 0.000 description 3
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 108010038764 cytoplasmic linker protein 170 Proteins 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 235000014304 histidine Nutrition 0.000 description 3
- 239000000710 homodimer Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000000527 lymphocytic effect Effects 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 238000002887 multiple sequence alignment Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 230000006337 proteolytic cleavage Effects 0.000 description 3
- 239000012857 radioactive material Substances 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- VYEWZWBILJHHCU-OMQUDAQFSA-N (e)-n-[(2s,3r,4r,5r,6r)-2-[(2r,3r,4s,5s,6s)-3-acetamido-5-amino-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[2-[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl]-4,5-dihydroxyoxan-3-yl]-5-methylhex-2-enamide Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)C(O)C[C@@H]2[C@H](O)[C@H](O)[C@H]([C@@H](O2)O[C@@H]2[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O2)NC(C)=O)NC(=O)/C=C/CC(C)C)C=CC(=O)NC1=O VYEWZWBILJHHCU-OMQUDAQFSA-N 0.000 description 2
- CXCHEKCRJQRVNG-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonyl chloride Chemical compound FC(F)(F)CS(Cl)(=O)=O CXCHEKCRJQRVNG-UHFFFAOYSA-N 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
- CJIJXIFQYOPWTF-UHFFFAOYSA-N 7-hydroxycoumarin Natural products O1C(=O)C=CC2=CC(O)=CC=C21 CJIJXIFQYOPWTF-UHFFFAOYSA-N 0.000 description 2
- 230000005730 ADP ribosylation Effects 0.000 description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 description 2
- 102100033639 Acetylcholinesterase Human genes 0.000 description 2
- 108010000239 Aequorin Proteins 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 102100026189 Beta-galactosidase Human genes 0.000 description 2
- 241000282461 Canis lupus Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 101710112752 Cytotoxin Proteins 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 102100020873 Interleukin-2 Human genes 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 101710182846 Polyhedrin Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108010007127 Pulmonary Surfactant-Associated Protein D Proteins 0.000 description 2
- 102100027845 Pulmonary surfactant-associated protein D Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 208000007660 Residual Neoplasm Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 241000011102 Thera Species 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 2
- VGQOVCHZGQWAOI-UHFFFAOYSA-N UNPD55612 Natural products N1C(O)C2CC(C=CC(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-UHFFFAOYSA-N 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 229940022698 acetylcholinesterase Drugs 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- VGQOVCHZGQWAOI-HYUHUPJXSA-N anthramycin Chemical compound N1[C@@H](O)[C@@H]2CC(\C=C\C(N)=O)=CN2C(=O)C2=CC=C(C)C(O)=C12 VGQOVCHZGQWAOI-HYUHUPJXSA-N 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 230000010516 arginylation Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000017858 demethylation Effects 0.000 description 2
- 238000010520 demethylation reaction Methods 0.000 description 2
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- 108020001096 dihydrofolate reductase Proteins 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 230000006251 gamma-carboxylation Effects 0.000 description 2
- 238000012817 gel-diffusion technique Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 125000003827 glycol group Chemical group 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 150000003278 haem Chemical group 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- 238000012188 high-throughput screening assay Methods 0.000 description 2
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000000951 immunodiffusion Effects 0.000 description 2
- 238000013394 immunophenotyping Methods 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000026045 iodination Effects 0.000 description 2
- 238000006192 iodination reaction Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- SXTAYKAGBXMACB-UHFFFAOYSA-N methionine S-imide-S-oxide Natural products CS(=N)(=O)CCC(N)C(O)=O SXTAYKAGBXMACB-UHFFFAOYSA-N 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 230000007498 myristoylation Effects 0.000 description 2
- ZTLGJPIZUOVDMT-UHFFFAOYSA-N n,n-dichlorotriazin-4-amine Chemical compound ClN(Cl)C1=CC=NN=N1 ZTLGJPIZUOVDMT-UHFFFAOYSA-N 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 230000036963 noncompetitive effect Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 229940080469 phosphocellulose Drugs 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000013823 prenylation Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 229940043131 pyroglutamate Drugs 0.000 description 2
- 230000006340 racemization Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000002708 random mutagenesis Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- 238000005670 sulfation reaction Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 238000011285 therapeutic regimen Methods 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 2
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 2
- HFTAFOQKODTIJY-UHFFFAOYSA-N umbelliferone Natural products Cc1cc2C=CC(=O)Oc2cc1OCC=CC(C)(C)O HFTAFOQKODTIJY-UHFFFAOYSA-N 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- QRYXYRQPMWQIDM-UHFFFAOYSA-N 3-benzoyl-3-(2,5-dioxopyrrol-1-yl)-1-hydroxypyrrolidine-2,5-dione Chemical compound O=C1N(O)C(=O)CC1(C(=O)C=1C=CC=CC=1)N1C(=O)C=CC1=O QRYXYRQPMWQIDM-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 101001084702 Arabidopsis thaliana Histone H2B.10 Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102100025222 CD63 antigen Human genes 0.000 description 1
- 102100027217 CD82 antigen Human genes 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 101100087530 Caenorhabditis elegans rom-1 gene Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 241000701489 Cauliflower mosaic virus Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 101150032685 Cd151 gene Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 230000010556 Heparin Binding Activity Effects 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
- 101000914469 Homo sapiens CD82 antigen Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000980823 Homo sapiens Leukocyte surface antigen CD53 Proteins 0.000 description 1
- 101000610652 Homo sapiens Peripherin-2 Proteins 0.000 description 1
- 101000847107 Homo sapiens Tetraspanin-8 Proteins 0.000 description 1
- 101000802084 Homo sapiens Thiosulfate sulfurtransferase Proteins 0.000 description 1
- 101000830596 Homo sapiens Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- XIGSAGMEBXLVJJ-YFKPBYRVSA-N L-homocitrulline Chemical compound NC(=O)NCCCC[C@H]([NH3+])C([O-])=O XIGSAGMEBXLVJJ-YFKPBYRVSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100024221 Leukocyte surface antigen CD53 Human genes 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- ZOKXTWBITQBERF-AKLPVKDBSA-N Molybdenum Mo-99 Chemical compound [99Mo] ZOKXTWBITQBERF-AKLPVKDBSA-N 0.000 description 1
- 101100305983 Mus musculus Rom1 gene Proteins 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 108010035042 Osteoprotegerin Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
- 102000009609 Pyrophosphatases Human genes 0.000 description 1
- 108010009413 Pyrophosphatases Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 101001012264 Schistosoma mansoni 23 kDa integral membrane protein Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 108050007496 Shikimate kinase 2 Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102100032802 Tetraspanin-8 Human genes 0.000 description 1
- 108700031126 Tetraspanins Proteins 0.000 description 1
- 102000043977 Tetraspanins Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 102100032236 Tumor necrosis factor receptor superfamily member 11B Human genes 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000007801 affinity label Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- RSIHSRDYCUFFLA-DYKIIFRCSA-N boldenone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 RSIHSRDYCUFFLA-DYKIIFRCSA-N 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003588 centroblast Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- NDAYQJDHGXTBJL-MWWSRJDJSA-N chembl557217 Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 NDAYQJDHGXTBJL-MWWSRJDJSA-N 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 238000003200 chromosome mapping Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- 231100000409 cytocidal Toxicity 0.000 description 1
- 230000000445 cytocidal effect Effects 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000003145 cytotoxic factor Substances 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- RSIHSRDYCUFFLA-UHFFFAOYSA-N dehydrotestosterone Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)O)C4C3CCC2=C1 RSIHSRDYCUFFLA-UHFFFAOYSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000006334 disulfide bridging Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 238000003017 in situ immunoassay Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 101150009573 phoA gene Proteins 0.000 description 1
- 239000003934 phosphoprotein phosphatase inhibitor Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 108010039177 polyphenylalanine Proteins 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 238000013197 protein A assay Methods 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 238000002416 scanning tunnelling spectroscopy Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- 208000011317 telomere syndrome Diseases 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229910052716 thallium Inorganic materials 0.000 description 1
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229940108519 trasylol Drugs 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229910001868 water Inorganic materials 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La présente invention concerne de nouvelles protéines. Plus spécialement, elle s'applique à des molécules d'acide nucléique isolées qui codent pour de nouveaux polypeptides. L'invention concerne des polypeptides et des anticorps. Elle concerne également des vecteurs, des cellules hôtes et des méthodes synthétiques et recombinantes permettant de produire des polynucléotides et/ou des polypeptides humains, ainsi que des anticorps. Par ailleurs, l'invention concerne des méthodes diagnostiques et thérapeutiques utiles pour le diagnostic, le traitement, la prévention e/ou le pronostic de troubles en rapport avec des nouveaux polypeptides. Sont également décrites des méthodes de criblage permettant d'identifier des agonistes et des antagonistes des polynucléotides et polypeptides de l'invention, ainsi que des méthodes et/ou des compositions propres à inhiber ou accentuer la production et la fonction des polypeptides selon l'invention.
Applications Claiming Priority (235)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17906500P | 2000-01-31 | 2000-01-31 | |
| US60/179,065 | 2000-01-31 | ||
| US18062800P | 2000-02-04 | 2000-02-04 | |
| US60/180,628 | 2000-02-04 | ||
| US18466400P | 2000-02-24 | 2000-02-24 | |
| US60/184,664 | 2000-02-24 | ||
| US18635000P | 2000-03-02 | 2000-03-02 | |
| US60/186,350 | 2000-03-02 | ||
| US18987400P | 2000-03-16 | 2000-03-16 | |
| US60/189,874 | 2000-03-16 | ||
| US19007600P | 2000-03-17 | 2000-03-17 | |
| US60/190,076 | 2000-03-17 | ||
| US19812300P | 2000-04-18 | 2000-04-18 | |
| US60/198,123 | 2000-04-18 | ||
| US20551500P | 2000-05-19 | 2000-05-19 | |
| US60/205,515 | 2000-05-19 | ||
| US20946700P | 2000-06-07 | 2000-06-07 | |
| US60/209,467 | 2000-06-07 | ||
| US21488600P | 2000-06-28 | 2000-06-28 | |
| US60/214,886 | 2000-06-28 | ||
| US21513500P | 2000-06-30 | 2000-06-30 | |
| US60/215,135 | 2000-06-30 | ||
| US21688000P | 2000-07-07 | 2000-07-07 | |
| US21664700P | 2000-07-07 | 2000-07-07 | |
| US60/216,880 | 2000-07-07 | ||
| US60/216,647 | 2000-07-07 | ||
| US21748700P | 2000-07-11 | 2000-07-11 | |
| US21749600P | 2000-07-11 | 2000-07-11 | |
| US60/217,496 | 2000-07-11 | ||
| US60/217,487 | 2000-07-11 | ||
| US21829000P | 2000-07-14 | 2000-07-14 | |
| US60/218,290 | 2000-07-14 | ||
| US22096300P | 2000-07-26 | 2000-07-26 | |
| US22096400P | 2000-07-26 | 2000-07-26 | |
| US60/220,963 | 2000-07-26 | ||
| US60/220,964 | 2000-07-26 | ||
| US22526600P | 2000-08-14 | 2000-08-14 | |
| US22575900P | 2000-08-14 | 2000-08-14 | |
| US22527000P | 2000-08-14 | 2000-08-14 | |
| US22521300P | 2000-08-14 | 2000-08-14 | |
| US22575800P | 2000-08-14 | 2000-08-14 | |
| US22526800P | 2000-08-14 | 2000-08-14 | |
| US22521400P | 2000-08-14 | 2000-08-14 | |
| US22544700P | 2000-08-14 | 2000-08-14 | |
| US22526700P | 2000-08-14 | 2000-08-14 | |
| US22451800P | 2000-08-14 | 2000-08-14 | |
| US22451900P | 2000-08-14 | 2000-08-14 | |
| US22575700P | 2000-08-14 | 2000-08-14 | |
| US60/225,759 | 2000-08-14 | ||
| US60/225,268 | 2000-08-14 | ||
| US60/225,447 | 2000-08-14 | ||
| US60/225,266 | 2000-08-14 | ||
| US60/224,519 | 2000-08-14 | ||
| US60/225,213 | 2000-08-14 | ||
| US60/224,518 | 2000-08-14 | ||
| US60/225,270 | 2000-08-14 | ||
| US60/225,758 | 2000-08-14 | ||
| US60/225,757 | 2000-08-14 | ||
| US60/225,267 | 2000-08-14 | ||
| US60/225,214 | 2000-08-14 | ||
| US22627900P | 2000-08-18 | 2000-08-18 | |
| US60/226,279 | 2000-08-18 | ||
| US22668100P | 2000-08-22 | 2000-08-22 | |
| US22718200P | 2000-08-22 | 2000-08-22 | |
| US22686800P | 2000-08-22 | 2000-08-22 | |
| US60/226,681 | 2000-08-22 | ||
| US60/226,868 | 2000-08-22 | ||
| US60/227,182 | 2000-08-22 | ||
| US22700900P | 2000-08-23 | 2000-08-23 | |
| US60/227,009 | 2000-08-23 | ||
| US22892400P | 2000-08-30 | 2000-08-30 | |
| US60/228,924 | 2000-08-30 | ||
| US22934500P | 2000-09-01 | 2000-09-01 | |
| US22928700P | 2000-09-01 | 2000-09-01 | |
| US22934300P | 2000-09-01 | 2000-09-01 | |
| US22934400P | 2000-09-01 | 2000-09-01 | |
| US60/229,287 | 2000-09-01 | ||
| US60/229,345 | 2000-09-01 | ||
| US60/229,343 | 2000-09-01 | ||
| US60/229,344 | 2000-09-01 | ||
| US22950900P | 2000-09-05 | 2000-09-05 | |
| US22951300P | 2000-09-05 | 2000-09-05 | |
| US60/229,509 | 2000-09-05 | ||
| US60/229,513 | 2000-09-05 | ||
| US23043700P | 2000-09-06 | 2000-09-06 | |
| US23043800P | 2000-09-06 | 2000-09-06 | |
| US60/230,437 | 2000-09-06 | ||
| US60/230,438 | 2000-09-06 | ||
| US23124400P | 2000-09-08 | 2000-09-08 | |
| US23124200P | 2000-09-08 | 2000-09-08 | |
| US23208100P | 2000-09-08 | 2000-09-08 | |
| US23208000P | 2000-09-08 | 2000-09-08 | |
| US23141300P | 2000-09-08 | 2000-09-08 | |
| US23124300P | 2000-09-08 | 2000-09-08 | |
| US23141400P | 2000-09-08 | 2000-09-08 | |
| US60/231,244 | 2000-09-08 | ||
| US60/231,414 | 2000-09-08 | ||
| US60/232,080 | 2000-09-08 | ||
| US60/231,242 | 2000-09-08 | ||
| US60/232,081 | 2000-09-08 | ||
| US60/231,243 | 2000-09-08 | ||
| US60/231,413 | 2000-09-08 | ||
| US23196800P | 2000-09-12 | 2000-09-12 | |
| US60/231,968 | 2000-09-12 | ||
| US23239900P | 2000-09-14 | 2000-09-14 | |
| US23306400P | 2000-09-14 | 2000-09-14 | |
| US23239700P | 2000-09-14 | 2000-09-14 | |
| US23240000P | 2000-09-14 | 2000-09-14 | |
| US23240100P | 2000-09-14 | 2000-09-14 | |
| US23239800P | 2000-09-14 | 2000-09-14 | |
| US23306300P | 2000-09-14 | 2000-09-14 | |
| US23306500P | 2000-09-14 | 2000-09-14 | |
| US60/232,400 | 2000-09-14 | ||
| US60/233,063 | 2000-09-14 | ||
| US60/233,065 | 2000-09-14 | ||
| US60/232,399 | 2000-09-14 | ||
| US60/232,398 | 2000-09-14 | ||
| US60/232,397 | 2000-09-14 | ||
| US60/232,401 | 2000-09-14 | ||
| US60/233,064 | 2000-09-14 | ||
| US23427400P | 2000-09-21 | 2000-09-21 | |
| US23422300P | 2000-09-21 | 2000-09-21 | |
| US60/234,274 | 2000-09-21 | ||
| US60/234,223 | 2000-09-21 | ||
| US23499700P | 2000-09-25 | 2000-09-25 | |
| US23499800P | 2000-09-25 | 2000-09-25 | |
| US60/234,998 | 2000-09-25 | ||
| US60/234,997 | 2000-09-25 | ||
| US23548400P | 2000-09-26 | 2000-09-26 | |
| US60/235,484 | 2000-09-26 | ||
| US23583600P | 2000-09-27 | 2000-09-27 | |
| US23583400P | 2000-09-27 | 2000-09-27 | |
| US60/235,836 | 2000-09-27 | ||
| US60/235,834 | 2000-09-27 | ||
| US23636900P | 2000-09-29 | 2000-09-29 | |
| US23632700P | 2000-09-29 | 2000-09-29 | |
| US23636800P | 2000-09-29 | 2000-09-29 | |
| US23636700P | 2000-09-29 | 2000-09-29 | |
| US23637000P | 2000-09-29 | 2000-09-29 | |
| US60/236,367 | 2000-09-29 | ||
| US60/236,369 | 2000-09-29 | ||
| US60/236,370 | 2000-09-29 | ||
| US60/236,368 | 2000-09-29 | ||
| US60/236,327 | 2000-09-29 | ||
| US23680200P | 2000-10-02 | 2000-10-02 | |
| US23703700P | 2000-10-02 | 2000-10-02 | |
| US23704000P | 2000-10-02 | 2000-10-02 | |
| US23703900P | 2000-10-02 | 2000-10-02 | |
| US23703800P | 2000-10-02 | 2000-10-02 | |
| US60/237,039 | 2000-10-02 | ||
| US60/236,802 | 2000-10-02 | ||
| US60/237,038 | 2000-10-02 | ||
| US60/237,040 | 2000-10-02 | ||
| US60/237,037 | 2000-10-02 | ||
| US23993700P | 2000-10-13 | 2000-10-13 | |
| US23993500P | 2000-10-13 | 2000-10-13 | |
| US60/239,937 | 2000-10-13 | ||
| US60/239,935 | 2000-10-13 | ||
| US24096000P | 2000-10-20 | 2000-10-20 | |
| US24178700P | 2000-10-20 | 2000-10-20 | |
| US24122100P | 2000-10-20 | 2000-10-20 | |
| US24180900P | 2000-10-20 | 2000-10-20 | |
| US24182600P | 2000-10-20 | 2000-10-20 | |
| US24178600P | 2000-10-20 | 2000-10-20 | |
| US24178500P | 2000-10-20 | 2000-10-20 | |
| US24180800P | 2000-10-20 | 2000-10-20 | |
| US60/241,809 | 2000-10-20 | ||
| US60/241,808 | 2000-10-20 | ||
| US60/241,826 | 2000-10-20 | ||
| US60/241,787 | 2000-10-20 | ||
| US60/241,786 | 2000-10-20 | ||
| US60/241,221 | 2000-10-20 | ||
| US60/240,960 | 2000-10-20 | ||
| US60/241,785 | 2000-10-20 | ||
| US24461700P | 2000-11-01 | 2000-11-01 | |
| US60/244,617 | 2000-11-01 | ||
| US24652500P | 2000-11-08 | 2000-11-08 | |
| US24652600P | 2000-11-08 | 2000-11-08 | |
| US24652700P | 2000-11-08 | 2000-11-08 | |
| US24647400P | 2000-11-08 | 2000-11-08 | |
| US24647600P | 2000-11-08 | 2000-11-08 | |
| US24652800P | 2000-11-08 | 2000-11-08 | |
| US24661100P | 2000-11-08 | 2000-11-08 | |
| US24653200P | 2000-11-08 | 2000-11-08 | |
| US24647500P | 2000-11-08 | 2000-11-08 | |
| US24647700P | 2000-11-08 | 2000-11-08 | |
| US24661000P | 2000-11-08 | 2000-11-08 | |
| US60/246,609 | 2000-11-08 | ||
| US60/246,525 | 2000-11-08 | ||
| US60/246,610 | 2000-11-08 | ||
| US60/246,474 | 2000-11-08 | ||
| US60/246,532 | 2000-11-08 | ||
| US60/246,611 | 2000-11-08 | ||
| US60/246,524 | 2000-11-08 | ||
| US60/246,523 | 2000-11-08 | ||
| US60/246,526 | 2000-11-08 | ||
| US60/246,527 | 2000-11-08 | ||
| US60/246,528 | 2000-11-08 | ||
| US60/246,478 | 2000-11-08 | ||
| US60/246,475 | 2000-11-08 | ||
| US60/246,476 | 2000-11-08 | ||
| US60/246,613 | 2000-11-08 | ||
| US60/246,477 | 2000-11-08 | ||
| US60/249,207 | 2000-11-17 | ||
| US60/249,300 | 2000-11-17 | ||
| US60/249,214 | 2000-11-17 | ||
| US60/249,216 | 2000-11-17 | ||
| US60/249,209 | 2000-11-17 | ||
| US60/249,297 | 2000-11-17 | ||
| US60/249,264 | 2000-11-17 | ||
| US60/249,208 | 2000-11-17 | ||
| US60/249,217 | 2000-11-17 | ||
| US60/249,213 | 2000-11-17 | ||
| US60/249,211 | 2000-11-17 | ||
| US60/249,215 | 2000-11-17 | ||
| US60/249,299 | 2000-11-17 | ||
| US60/249,265 | 2000-11-17 | ||
| US60/249,244 | 2000-11-17 | ||
| US60/249,210 | 2000-11-17 | ||
| US60/249,212 | 2000-11-17 | ||
| US60/249,218 | 2000-11-17 | ||
| US60/249,245 | 2000-11-17 | ||
| US60/250,160 | 2000-12-01 | ||
| US60/250,391 | 2000-12-01 | ||
| US60/251,030 | 2000-12-05 | ||
| US60/256,719 | 2000-12-05 | ||
| US60/251,988 | 2000-12-05 | ||
| US60/251,479 | 2000-12-06 | ||
| US60/251,856 | 2000-12-08 | ||
| US60/251,989 | 2000-12-08 | ||
| US60/251,990 | 2000-12-08 | ||
| US60/251,868 | 2000-12-08 | ||
| US60/251,869 | 2000-12-08 | ||
| US60/254,097 | 2000-12-11 | ||
| US60/259,678 | 2001-01-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2395738A1 true CA2395738A1 (fr) | 2002-08-02 |
Family
ID=27587117
Family Applications (37)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002395827A Withdrawn CA2395827A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002392450A Abandoned CA2392450A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395295A Withdrawn CA2395295A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002393652A Withdrawn CA2393652A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395693A Pending CA2395693A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395849A Pending CA2395849A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395671A Withdrawn CA2395671A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002392428A Abandoned CA2392428A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002392422A Abandoned CA2392422A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002393002A Withdrawn CA2393002A1 (fr) | 2000-01-31 | 2001-01-17 | Acides ncleiques, proteines et anticorps |
| CA002395724A Pending CA2395724A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002392398A Abandoned CA2392398A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002397839A Withdrawn CA2397839A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395787A Withdrawn CA2395787A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002394039A Abandoned CA2394039A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395654A Withdrawn CA2395654A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395178A Withdrawn CA2395178A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395734A Withdrawn CA2395734A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002392438A Abandoned CA2392438A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395816A Withdrawn CA2395816A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395858A Withdrawn CA2395858A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002398411A Withdrawn CA2398411A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395885A Withdrawn CA2395885A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002398877A Withdrawn CA2398877A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002393912A Withdrawn CA2393912A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395729A Pending CA2395729A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395403A Withdrawn CA2395403A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002397407A Withdrawn CA2397407A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395699A Pending CA2395699A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002394841A Withdrawn CA2394841A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395738A Withdrawn CA2395738A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395872A Withdrawn CA2395872A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395666A Withdrawn CA2395666A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002393618A Abandoned CA2393618A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395398A Withdrawn CA2395398A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines, et anticorps |
| CA002392751A Abandoned CA2392751A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002392757A Abandoned CA2392757A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
Family Applications Before (30)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002395827A Withdrawn CA2395827A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002392450A Abandoned CA2392450A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395295A Withdrawn CA2395295A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002393652A Withdrawn CA2393652A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395693A Pending CA2395693A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395849A Pending CA2395849A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395671A Withdrawn CA2395671A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002392428A Abandoned CA2392428A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002392422A Abandoned CA2392422A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002393002A Withdrawn CA2393002A1 (fr) | 2000-01-31 | 2001-01-17 | Acides ncleiques, proteines et anticorps |
| CA002395724A Pending CA2395724A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002392398A Abandoned CA2392398A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002397839A Withdrawn CA2397839A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395787A Withdrawn CA2395787A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002394039A Abandoned CA2394039A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395654A Withdrawn CA2395654A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395178A Withdrawn CA2395178A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395734A Withdrawn CA2395734A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002392438A Abandoned CA2392438A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395816A Withdrawn CA2395816A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395858A Withdrawn CA2395858A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002398411A Withdrawn CA2398411A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395885A Withdrawn CA2395885A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002398877A Withdrawn CA2398877A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002393912A Withdrawn CA2393912A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395729A Pending CA2395729A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395403A Withdrawn CA2395403A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002397407A Withdrawn CA2397407A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395699A Pending CA2395699A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002394841A Withdrawn CA2394841A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002395872A Withdrawn CA2395872A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395666A Withdrawn CA2395666A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002393618A Abandoned CA2393618A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002395398A Withdrawn CA2395398A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines, et anticorps |
| CA002392751A Abandoned CA2392751A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
| CA002392757A Abandoned CA2392757A1 (fr) | 2000-01-31 | 2001-01-17 | Acides nucleiques, proteines et anticorps |
Country Status (3)
| Country | Link |
|---|---|
| AU (16) | AU2001241415A1 (fr) |
| CA (37) | CA2395827A1 (fr) |
| WO (48) | WO2001055320A2 (fr) |
Families Citing this family (273)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001070982A2 (fr) * | 2000-03-23 | 2001-09-27 | Immusol Incorporated | Regulateurs de brca-1 et procedes d'utilisation |
| US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US7258860B2 (en) | 1998-03-18 | 2007-08-21 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US6960570B2 (en) | 1998-03-18 | 2005-11-01 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
| US7579160B2 (en) | 1998-03-18 | 2009-08-25 | Corixa Corporation | Methods for the detection of cervical cancer |
| US6706262B1 (en) | 1998-03-18 | 2004-03-16 | Corixa Corporation | Compounds and methods for therapy and diagnosis of lung cancer |
| US7771719B1 (en) | 2000-01-11 | 2010-08-10 | Genentech, Inc. | Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E |
| NZ508878A (en) | 1998-05-15 | 2003-08-29 | Genentech Inc | IL-17B and IL-17Cactive variants of IL-17 which stimulates epithelial, endothelial and fibroblastic cells |
| US6929938B2 (en) | 2001-08-15 | 2005-08-16 | Millennium Pharmaceuticals, Inc. | 25501, a human transferase family member and uses therefor |
| US7141417B1 (en) | 1999-02-25 | 2006-11-28 | Thomas Jefferson University | Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene |
| EP1163252A4 (fr) * | 1999-02-25 | 2004-04-07 | Univ Jefferson | Compositions, kits et procedes concernant le gene fez1 de l'homme, nouveau gene suppresseur des tumeurs |
| WO2000050458A1 (fr) * | 1999-02-26 | 2000-08-31 | Smithkline Beecham Corporation | Clonage du recepteur 7tm (axor 17) du type p2y |
| WO2000056881A1 (fr) * | 1999-03-23 | 2000-09-28 | Human Genome Sciences, Inc. | 48 proteines humaines secretees |
| WO2000058480A1 (fr) * | 1999-03-29 | 2000-10-05 | Kansai Technology Licensing Organization Co., Ltd. | Nouvelle cytidine desaminase |
| EP1621620A3 (fr) * | 1999-09-01 | 2006-05-10 | Genetech, Inc. | Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci |
| WO2001030971A2 (fr) * | 1999-10-27 | 2001-05-03 | Millennium Pharmaceuticals, Inc. | Nouvelles molecules de la famille des proteines se rapportant aux card et leurs utilisations |
| US6893818B1 (en) | 1999-10-28 | 2005-05-17 | Agensys, Inc. | Gene upregulated in cancers of the prostate |
| US7005499B1 (en) * | 1999-11-18 | 2006-02-28 | Genentech, Inc. | Wnt-regulated cytokine-like polypeptide and nucleic acids encoding same |
| EP1878794A3 (fr) * | 1999-11-30 | 2008-01-23 | Genentech, Inc. | Compositions et procédés pour le traitement de maladies liées au système immunitaire |
| EP1686134A3 (fr) * | 1999-12-01 | 2006-08-09 | Genentech, Inc. | Polypeptides transmembranaires et secrétés et les acides nucléiques codant ceux-ci |
| CN1300781A (zh) * | 1999-12-22 | 2001-06-27 | 上海博德基因开发有限公司 | 一种新的多肽-人shc蛋白43和编码这种多肽的多核苷酸 |
| US20040043397A1 (en) | 2000-01-11 | 2004-03-04 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| AU3797301A (en) | 2000-01-26 | 2001-08-07 | Urogenesys Inc | 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer |
| US6953682B2 (en) | 2000-02-10 | 2005-10-11 | Millennium Pharmaceuticals, Inc. | Nucleic acid sequences encoding adenylate kinase, phospholipid scramblase-like, DNA fragmentation factor-like, phosphatidylserine synthase-like, and atpase-like molecules and uses therefor |
| US20020082212A1 (en) * | 2000-07-20 | 2002-06-27 | Millennium Pharmaceuticals, Inc. | 7716, a novel human ATPase and uses therefor |
| US7078205B2 (en) | 2000-02-17 | 2006-07-18 | Millennium Pharmaceuticals, Inc. | Nucleic acid sequences encoding melanoma associated antigen molecules, aminotransferase molecules, atpase molecules, acyltransferase molecules, pyridoxal-phosphate dependent enzyme molecules and uses therefor |
| US20020031815A1 (en) * | 2000-06-26 | 2002-03-14 | Millennium Pharmaceuticals, Inc. | 46619, a novel human beta-ketoacyl synthase and uses thereof |
| US20020090705A1 (en) * | 2000-07-14 | 2002-07-11 | Rachel Meyers | 62088, a novel human nucleoside phosphatase family member and uses thereof |
| US7718397B2 (en) | 2000-03-21 | 2010-05-18 | Genentech, Inc. | Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof |
| EP1272640A2 (fr) | 2000-03-24 | 2003-01-08 | Millennium Pharmaceuticals, Inc. | 3714, 16742, 23546, et 13887 nouvelles molecules de proteine kinase et leurs utilisations |
| US20030198953A1 (en) * | 2000-03-30 | 2003-10-23 | Spytek Kimberly A. | Novel proteins and nucleic acids encoding same |
| US7632929B2 (en) | 2000-04-20 | 2009-12-15 | The Board Of Trustees Of The University Of Arkansas | Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof |
| AU2001257195B2 (en) * | 2000-04-25 | 2006-10-05 | Lexicon Pharmaceuticals, Inc. | Novel human kinase proteins and polynucleotides encoding the same |
| AU2001257407A1 (en) * | 2000-04-26 | 2001-11-07 | Millennium Pharmaceuticals, Inc. | 21657, a human short-chain dehydrogenase and uses thereof |
| US6808876B1 (en) * | 2000-05-02 | 2004-10-26 | Immusol, Inc. | Cellular regulators of infectious agents and methods of use |
| WO2001085921A2 (fr) * | 2000-05-12 | 2001-11-15 | Merck Patent Gmbh | Nouvelle serine-threonine kinase-4 |
| EP1158001B1 (fr) * | 2000-05-26 | 2007-11-14 | F. Hoffmann-La Roche Ag | Un acide nucléique produit excessivement dans des cellules tumorales humaines, une protéine codée par ledit acide nucléique et un procédé de diagnose de tumeurs |
| US20040175815A1 (en) * | 2000-05-26 | 2004-09-09 | Yonghong Xiao | Regulation of human p78-like serube/threonine kinase |
| DE10027170A1 (de) * | 2000-05-31 | 2001-12-13 | Schering Ag | Humanes PEM als Target für die Fertilitätskontrolle |
| AU6531101A (en) * | 2000-06-02 | 2001-12-17 | Genentech Inc | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| US20030096969A1 (en) | 2000-06-02 | 2003-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| WO2001093805A2 (fr) * | 2000-06-02 | 2001-12-13 | The Brigham & Women's Hospital, Inc. | Fusion de genes jazf1 et jjaz1 dans des tumeurs stromatolithiques endometriales |
| AU6604901A (en) * | 2000-06-05 | 2001-12-17 | Bayer Aktiengesellschaft | Regulation of human hm74-like g protein coupled receptor |
| WO2001096390A2 (fr) * | 2000-06-09 | 2001-12-20 | Corixa Corporation | Compositions et procedes pour la therapie et le diagnostic du cancer du colon |
| US6323016B1 (en) | 2000-06-09 | 2001-11-27 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| AU2001268435A1 (en) * | 2000-06-15 | 2001-12-24 | Millennium Pharmaceuticals, Inc. | 23680, a novel human aminotransferase and uses therefor |
| JP2004513620A (ja) * | 2000-06-16 | 2004-05-13 | インサイト・ゲノミックス・インコーポレイテッド | プロテインホスファターゼ |
| EP2168980A1 (fr) * | 2000-06-23 | 2010-03-31 | Genentech, Inc. | Compositions et procédés pour le traitement et le diagnostic des troubles impliquant une angiogenèse |
| US7094587B2 (en) | 2000-06-27 | 2006-08-22 | Millennium Pharmaceuticals, Inc. | 16002 Molecules and uses therefor |
| EP1309684A2 (fr) * | 2000-06-27 | 2003-05-14 | Curagen Corporation | Polynucleotides et polypeptides codes par ceux-ci |
| WO2002000939A2 (fr) | 2000-06-28 | 2002-01-03 | Diadexus, Inc. | Procede de diagnostic, de surveillance, de determination du stade, d'imagerie et de traitement du cancer du colon |
| US6900303B2 (en) | 2000-06-30 | 2005-05-31 | Millennium Pharmaceuticals, Inc. | 57658, a novel human uridine kinase and uses thereof |
| EP1313854A2 (fr) * | 2000-07-07 | 2003-05-28 | Incyte Genomics, Inc. | Transporteurs et canneaux d'ion |
| AU2001271843A1 (en) * | 2000-07-07 | 2002-01-21 | Incyte Genomics, Inc. | Gtp-binding proteins |
| WO2002006318A2 (fr) * | 2000-07-18 | 2002-01-24 | Board Of Regents, The University Of Texas System | Procedes et compositions permettant de stabiliser des microtubules et des filaments intermediaires dans des cellules de muscle strie |
| WO2002006453A2 (fr) * | 2000-07-18 | 2002-01-24 | Bayer Aktiengesellschaft | Regulation de protease a serine humaine de type desc1 |
| JP2004514420A (ja) * | 2000-07-20 | 2004-05-20 | ジェネンテック・インコーポレーテッド | 分泌及び膜貫通ポリペプチドとそれをコードする核酸 |
| US20060252034A1 (en) * | 2000-07-25 | 2006-11-09 | Klaus Duecker | Novel protein containing ring finger domaine r1p4 |
| WO2002008281A2 (fr) * | 2000-07-26 | 2002-01-31 | Stanford University | Proteine bstp-cad et reactifs associes et methodes d'utilisation |
| WO2002008282A2 (fr) * | 2000-07-26 | 2002-01-31 | Stanford University | Proteine bstp-ras/rerg et reactifs apparentes, procedes d'utilisation de ces derniers |
| EP1657254A3 (fr) * | 2000-08-01 | 2006-06-07 | Genentech, Inc. | Polypeptide, acides nucléiques le codant, et leur utilisation pour le diagnostic du cancer |
| US7335732B2 (en) | 2000-08-01 | 2008-02-26 | Genentech, Inc. | PRO9799 polypeptides |
| EP1315431A1 (fr) * | 2000-08-02 | 2003-06-04 | Millennium Pharmaceuticals, Inc. | Membre de la famille du facteur de liberation du gtp humain (15368) et ses utilisations |
| WO2002010217A2 (fr) | 2000-08-02 | 2002-02-07 | The Johns Hopkins University | Profils d'expression de cellules endotheliales |
| AU2001288231A1 (en) * | 2000-08-04 | 2002-02-18 | Zymogenetics Inc. | Human secreted protein, zzp1 |
| AU2001281252A1 (en) | 2000-08-10 | 2002-02-18 | Board Of Regents, The University Of Texas System | The tumor suppressor car-1 |
| US7091022B2 (en) * | 2000-08-11 | 2006-08-15 | Merck Patent Gmbh | Mitogen activated kinase |
| EP1326985A1 (fr) * | 2000-08-18 | 2003-07-16 | MERCK PATENT GmbH | Identification d'un gene d'acetyltransferase n-terminale humaine |
| US6962799B2 (en) * | 2000-08-21 | 2005-11-08 | Incyte Corporation | Microtubule-associated proteins and tubulins |
| US6706513B2 (en) | 2000-08-21 | 2004-03-16 | Bristol-Myers Squibb Company | Adenosine deaminase homolog |
| WO2002016579A2 (fr) * | 2000-08-24 | 2002-02-28 | Eli Lilly And Company | Acides nucleiques, vecteurs, cellules hotes, polypeptides et utilisations de ces derniers |
| AU8846601A (en) | 2000-08-28 | 2002-03-13 | Agensys Inc | Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer |
| EP1313761A4 (fr) * | 2000-08-28 | 2005-01-26 | Human Genome Sciences Inc | 18 proteines humaines secretees |
| EP1334189A2 (fr) * | 2000-08-28 | 2003-08-13 | AstraZeneca AB | Molecules impliquees dans la regulation du syndrome de resistance a l'insuline |
| AU2002210464A1 (en) * | 2000-08-30 | 2002-03-13 | Bayer Aktiengesellschaft | Regulation of human aminotransferase-like enzyme |
| US20020146800A1 (en) * | 2000-08-30 | 2002-10-10 | Curtis Rory A.J. | 48921, a novel human GTP releasing factor and uses therefor |
| WO2002018573A2 (fr) * | 2000-08-30 | 2002-03-07 | Millennium Pharmaceuticals, Inc. | Nouveau transporteur humain de sulfate: la proteine 54370, et utilisations associees |
| AU2001285908A1 (en) * | 2000-08-30 | 2002-03-13 | Bayer Aktiengesellschaft | Regulation of human aminotransferase-like enzyme |
| AU2001288600A1 (en) | 2000-08-31 | 2002-03-13 | Millennium Pharmaceuticals, Inc. | 62112, a novel human dehydrogenase and uses thereof |
| ES2327102T3 (es) * | 2000-09-05 | 2009-10-26 | Amgen Inc. | Moleculas analogas al receptor de tnf y usos de las mismas. |
| EP1364015A2 (fr) * | 2000-09-05 | 2003-11-26 | Incyte Genomics, Inc. | Molecules pour diagnostic et traitement |
| AU2001288999A1 (en) * | 2000-09-08 | 2002-03-22 | Millennium Pharmaceuticals, Inc. | 38646, a guanine nucleotide exchange factor and uses therefor |
| US6391606B1 (en) * | 2000-09-14 | 2002-05-21 | Pe Corporation | Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses thereof |
| US6372468B1 (en) | 2000-09-14 | 2002-04-16 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| JP2004531203A (ja) * | 2000-10-05 | 2004-10-14 | キュラジェン コーポレイション | ヒトタンパク質、これらをコードするポリヌクレオチド、ならびにこれらの利用方法 |
| AU2002220613A1 (en) * | 2000-10-11 | 2002-04-22 | Bayer Aktiengesellschaft | Regulation of human cyclophilin-type peptidyl-prolyl cis-trans isomerase |
| WO2002031132A2 (fr) * | 2000-10-11 | 2002-04-18 | Millennium Pharmaceuticals, Inc. | Nouvel element de la famille des phosphatases humaines a double specificite, appele 8843, et utilisation de ce dernier |
| US20020064831A1 (en) * | 2000-10-12 | 2002-05-30 | The Texas A&M University System | Nucleic acid sequences encoding CMG proteins, CMG proteins, and methods for their use |
| EP1474528A4 (fr) * | 2000-10-13 | 2006-06-14 | Protein Design Labs Inc | Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate |
| US6531297B2 (en) * | 2000-10-20 | 2003-03-11 | Applera Corporation | Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof |
| AU2002249787A1 (en) | 2000-10-25 | 2002-08-19 | Diadexus, Inc. | Compositions and methods relating to lung specific genes and proteins |
| WO2002036781A2 (fr) * | 2000-10-31 | 2002-05-10 | Bayer Aktiengesellschaft | Regulation de la glutathione-s-transferase humaine |
| AU2002229011A1 (en) * | 2000-11-09 | 2002-05-21 | Glaxo Group Limited | Deaminase catalyzing the removal of the cyclopropyl moiety from abacavir-mp |
| WO2002040672A2 (fr) | 2000-11-20 | 2002-05-23 | Diadexus, Inc. | Compositions et methodes relatives a des genes et des proteines specifiques aux seins |
| AU2001297765A1 (en) * | 2000-12-05 | 2002-10-21 | Incyte Genomics, Inc. | Ligases |
| EP1415005B1 (fr) | 2000-12-07 | 2012-11-21 | Novartis Vaccines and Diagnostics, Inc. | Retrovirus endogenes regules positivement dans le cancer de la prostate |
| US6692748B2 (en) | 2000-12-07 | 2004-02-17 | Zymogenetics, Inc. | Adipocyte complement related protein zacrp3x2 and nucleic acids encoding zacrp3x2 |
| AU2002211305A1 (en) * | 2000-12-14 | 2002-06-24 | Pe Corporation (Ny) | Isolated human kinase proteins, their encoding nucleic acid molecules, and uses thereof |
| US20020142376A1 (en) * | 2000-12-20 | 2002-10-03 | Gennady Merkulov | Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| US7892730B2 (en) * | 2000-12-22 | 2011-02-22 | Sagres Discovery, Inc. | Compositions and methods for cancer |
| ATE329027T1 (de) | 2000-12-22 | 2006-06-15 | Brystol Myers Squibb Company | Menschliches leucinereiche wiederholungen enthaltendes protein, vorwiegend im dünndarm exprimiert, hlrrsi1 |
| US6423521B1 (en) * | 2000-12-28 | 2002-07-23 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| WO2002053591A1 (fr) * | 2000-12-30 | 2002-07-11 | Lion Bioscience Ag | Cofacteur de recepteur nucleaire mammalien cf12 et ses procedes d'utilisation |
| WO2002053754A2 (fr) * | 2001-01-08 | 2002-07-11 | Lexicon Genetics Incorporated | Nouvelle protease humaine et polynucleotides codant cette derniere |
| AU2002243750A1 (en) * | 2001-01-30 | 2002-08-12 | Regeneron Pharmaceuticals, Inc. | Novel nucleic acid and polypeptide molecules |
| EP1409536A2 (fr) * | 2001-02-12 | 2004-04-21 | Curagen Corporation | Proteines, polynucleotides codant pour lesdites proteines et methodes d'utilisation desdites proteines |
| EP1637601A3 (fr) * | 2001-02-21 | 2006-03-29 | Curagen Corporation | Protéines , polynucléotides codant pour ces protéines et procédés d'utilisation |
| US7271240B2 (en) | 2001-03-14 | 2007-09-18 | Agensys, Inc. | 125P5C8: a tissue specific protein highly expressed in various cancers |
| WO2002074906A2 (fr) * | 2001-03-16 | 2002-09-26 | Eli Lilly And Company | Proteines de mammiferes lp et reactifs associes |
| US6913904B2 (en) * | 2001-03-27 | 2005-07-05 | Applera Corporation | Isolated human Ras-like proteins, nucleic acid molecules encoding these human Ras-like proteins, and uses thereof |
| EP1383922A4 (fr) | 2001-04-10 | 2005-03-30 | Agensys Inc | Acide nucleique et proteine correspondante intitule 158p3d2 utiles dans le traitement et la detection du cancer |
| CA2443147A1 (fr) | 2001-04-10 | 2002-10-24 | Agensys, Inc. | Acide nucleique et proteine correspondante intitulee 184p1e2, utilises dans le traitement et la detection de cancers |
| AU2002318112B2 (en) | 2001-04-10 | 2007-12-06 | Agensys, Inc. | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers |
| CN1505637A (zh) * | 2001-04-24 | 2004-06-16 | ��V��ҩ��ʽ���� | 克罗恩氏病抗体结合性肽以及克罗恩氏病检查方法 |
| AU2002249453A1 (en) * | 2001-04-24 | 2002-11-05 | Isis Innovation Ltd | Enzyme and snp marker for disease |
| KR100817467B1 (ko) | 2001-05-07 | 2008-03-31 | 시오노기세이야쿠가부시키가이샤 | 혈관신생 마커로서 사용되는 폴리펩티드 및 이의 ｄｎａ |
| AU2002314048A1 (en) * | 2001-05-09 | 2002-11-18 | Bayer Aktiengesellschaft | Regulation of human phosphatidic acid phosphatase type 2c-like protein |
| US7235358B2 (en) | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
| WO2003000901A2 (fr) * | 2001-06-26 | 2003-01-03 | Decode Genetics Ehf. | Acides nucleiques codant des proteines kinases |
| US20030120040A1 (en) | 2001-06-29 | 2003-06-26 | Genentech, Inc. | Secreted and Transmembrane polypeptides and nucleic acids encoding the same |
| GB2399086A (en) * | 2001-08-02 | 2004-09-08 | Aeomica Inc | Human zinc finger containing gene MDZ4 |
| AU2002359242A1 (en) * | 2001-08-17 | 2003-04-22 | Incyte Genomics, Inc. | Intracellular signaling molecules |
| US7270960B2 (en) * | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
| WO2003023063A1 (fr) * | 2001-09-07 | 2003-03-20 | Sankyo Company, Limited | Methode d'estimation du risque d'apparition de diabetes |
| WO2003025175A2 (fr) * | 2001-09-17 | 2003-03-27 | Molecular Engines Laboratories | Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments |
| WO2003040369A2 (fr) * | 2001-09-17 | 2003-05-15 | Molecular Engines Laboratories | Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments |
| ATE494363T1 (de) | 2001-09-28 | 2011-01-15 | Univ Brigham Young | Neue cyclooxygenase-varianten und verwendungsverfahren |
| WO2003038087A1 (fr) | 2001-10-04 | 2003-05-08 | Kansai Technology Licensing Organization Co., Ltd. | Promoteur du gene dr5 et promoteur du gene siah-1 |
| US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| WO2003031607A1 (fr) * | 2001-10-10 | 2003-04-17 | Bayer Healthcare Ag | Regulation de deshydrogenase/reductase des chaines courtes humaine |
| ATE364690T1 (de) | 2001-11-09 | 2007-07-15 | Proteologics Inc | Posh nukleinsäure, polypeptide und darauf bezogene verfahren |
| WO2003054146A2 (fr) | 2001-11-14 | 2003-07-03 | Northwestern University | Auto-assemblage et mineralisation de nanofibres de peptide amphiphile |
| US20050053940A1 (en) * | 2001-11-21 | 2005-03-10 | Joh-E Ikeda | Huntington's disease gene transcriptional factors |
| US7151162B2 (en) | 2001-12-06 | 2006-12-19 | The University Of Children's Hospital Of Both Cantons Of Basel | Nuclear protein |
| WO2003051911A2 (fr) * | 2001-12-19 | 2003-06-26 | Genset S.A. | Polypeptides et polynucleotides gmg-5 et utilisations de ceux-ci |
| JP2003245084A (ja) | 2001-12-20 | 2003-09-02 | Morinaga Milk Ind Co Ltd | 脳梁又は精子の形成不全の診断及び治療に有用な新規遺伝子、並びにその用途 |
| DE10163467A1 (de) * | 2001-12-21 | 2003-11-27 | Axaron Bioscience Ag | Protein 24B2 und zugrundliegende DNA-Sequenz |
| US6759222B2 (en) | 2002-01-02 | 2004-07-06 | Millennium Pharmaceuticals, Inc. | 14815, a human kinase family member and uses therefor |
| AU2003202543A1 (en) * | 2002-01-07 | 2003-07-24 | Bayer Aktiengesellschaft | Human phosphatidic acid phosphatase type 2-like protein |
| WO2003060109A2 (fr) * | 2002-01-15 | 2003-07-24 | Bayer Healthcare Ag | Regulation d'une subtilase humaine |
| AU2003205611A1 (en) * | 2002-01-15 | 2003-07-30 | Medigene Ag | Dilated cardiomyopathy associated gene-2 (dcmag-2): a cytoplasmatic inducer of sarcomeric remodeling in cardiomyocytes |
| WO2003062429A1 (fr) * | 2002-01-23 | 2003-07-31 | Yamanouchi Pharmaceutical Co., Ltd. | Nouvelle serine protease |
| US7371719B2 (en) | 2002-02-15 | 2008-05-13 | Northwestern University | Self-assembly of peptide-amphiphile nanofibers under physiological conditions |
| EP1338609A1 (fr) * | 2002-02-21 | 2003-08-27 | MEMOREC Stoffel GmbH-Medizinisch-Molekulare Entwicklung, Köln | Un outre récepteur KDR et son utilisation |
| CA2478271A1 (fr) * | 2002-03-05 | 2003-09-18 | Applera Corporation | Proteines transporteuses humaines isolees, molecules d'acide nucleique codant celles-ci, et utilisations associees |
| AU2003208472A1 (en) * | 2002-03-06 | 2003-09-16 | Oxford Glycosciences (Uk) Ltd | Novel b-cell malignancy-associated protein |
| EP2241636A1 (fr) | 2002-03-13 | 2010-10-20 | Genomic Health, Inc. | Profilage de l'expression génétique dans des tissus de tumeurs prélevées par biopsie |
| US7527935B2 (en) | 2002-03-19 | 2009-05-05 | Mitsubishi Tanabe Pharma Corporation | G-protein coupled receptor having eicosanoid as ligand and gene thereof |
| JP3949111B2 (ja) * | 2002-03-19 | 2007-07-25 | 田辺製薬株式会社 | 新規ｇタンパク質共役型受容体およびその遺伝子 |
| GB0206684D0 (en) * | 2002-03-21 | 2002-05-01 | Babraham Inst | Novel proteins |
| US7193069B2 (en) * | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| CA2413475C (fr) | 2002-04-25 | 2010-07-27 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Expression de zap-70 en tant que marqueur de la leucemie chronique lymphoide/du lymphome a petits lymphocytes (lcl/lpl) |
| JP2004041003A (ja) * | 2002-05-17 | 2004-02-12 | Takeda Chem Ind Ltd | 新規タンパク質、そのｄｎａおよびその用途 |
| EP1507553A2 (fr) | 2002-05-29 | 2005-02-23 | DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung | Proteines specifiques du pancreas |
| WO2003101401A2 (fr) | 2002-06-03 | 2003-12-11 | Chiron Corporation | Utilisation de nrg4, ou d'inhibiteurs de nrg4, dans le traitement du cancer du colon et du pancreas |
| EP2275544A3 (fr) * | 2002-06-06 | 2011-03-30 | Oncotherapy Science, Inc. | Gènes et polypeptides en rapport avec les cancers du colon chez l'homme |
| US8518694B2 (en) | 2002-06-13 | 2013-08-27 | Novartis Vaccines And Diagnostics, Inc. | Nucleic acid vector comprising a promoter and a sequence encoding a polypeptide from the endogenous retrovirus PCAV |
| US20060172296A1 (en) * | 2002-07-22 | 2006-08-03 | Masahiro Takeuchi | Novel gene associated with rheumatoid arthritis |
| JP4186004B2 (ja) | 2002-08-14 | 2008-11-26 | 独立行政法人産業技術総合研究所 | 新規ｎ−アセチルガラクトサミン転移酵素およびそれをコードする核酸 |
| AU2003243151A1 (en) | 2002-08-16 | 2004-03-03 | Agensys, Inc. | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer |
| AU2003235316A1 (en) * | 2002-08-23 | 2004-03-11 | Japan Science And Technology Agency | Human solid cancer antigen peptides, polynucleotides encoding the same and utilization thereof |
| EP1540014A2 (fr) * | 2002-08-27 | 2005-06-15 | Epigenomics AG | Procede et acides nucleiques servant a l'analyse de troubles lies a la proliferation des cellules mammaires |
| US7452969B2 (en) | 2002-08-30 | 2008-11-18 | Licentia Ltd | Neurotrophic factor protein and uses thereof |
| WO2007068784A1 (fr) | 2005-12-14 | 2007-06-21 | Licentia Ltd | Nouveau facteur neurotrophique et utilisations de celui-ci |
| ES2320443T3 (es) * | 2002-09-30 | 2009-05-22 | Oncotherapy Science, Inc. | Genes y polipeptidos relacionados con canceres pancreaticos humanos. |
| EP1552310A2 (fr) * | 2002-10-17 | 2005-07-13 | EVOTEC Neurosciences GmbH | L'utilisation de la proteine et du gene de la nicotinamide mononucleotide adenylyltransferase 2 (nmnat-2) pour le diagnostique et la therapie des maladies neurodegeneratives |
| AU2002952216A0 (en) * | 2002-10-23 | 2002-11-07 | The Walter And Eliza Hall Institute Of Medical Research | Novel therapeutic molecules |
| US7554021B2 (en) | 2002-11-12 | 2009-06-30 | Northwestern University | Composition and method for self-assembly and mineralization of peptide amphiphiles |
| WO2004046386A1 (fr) | 2002-11-15 | 2004-06-03 | Genomic Health, Inc. | Etablissement de profils d'expressions genetique du cancer a recepteur de facteur de croissance epidermique positif |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| AU2003287764B2 (en) * | 2002-12-13 | 2010-01-21 | The Walter And Eliza Hall Institute Of Medical Research | A novel phosphoprotein |
| AU2002953341A0 (en) * | 2002-12-13 | 2003-01-09 | The Walter And Eliza Hall Institute Of Medical Research | A novel phosphoprotein |
| US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
| US7326768B2 (en) | 2003-02-05 | 2008-02-05 | Juan Saus | Goodpasture antigen-binding protein isoforms and protein misfolded-mediated disorders |
| EP1445614A1 (fr) * | 2003-02-06 | 2004-08-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Méthodes d'évaluation in vitro de l'état de progression d'un virus HIV chez un individu |
| US7074891B2 (en) | 2003-02-07 | 2006-07-11 | Posco | Leukocyte stimulating peptides |
| AU2004213871B9 (en) | 2003-02-20 | 2009-09-03 | Genomic Health, Inc. | Use of intronic RNA to measure gene expression |
| CA2517953A1 (fr) * | 2003-03-04 | 2004-09-16 | Astellas Pharma Inc. | Nouveau gene associe a des conditions fibreuses |
| ATE479754T1 (de) * | 2003-03-19 | 2010-09-15 | Biogen Idec Inc | Nogo rezeptor bindendes protein |
| ITRM20030149A1 (it) | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| DK3170906T3 (en) | 2003-06-24 | 2018-11-05 | Genomic Health Inc | PREDICTION OF THE LIKELI REVENUE OF CANCER |
| WO2005008213A2 (fr) | 2003-07-10 | 2005-01-27 | Genomic Health, Inc. | Algorithme de profile d'expression et test du pronostic du cancer |
| WO2005014818A1 (fr) | 2003-08-08 | 2005-02-17 | Perseus Proteomics Inc. | Gene surexprime dans le cancer |
| US20050136434A1 (en) * | 2003-08-12 | 2005-06-23 | Mai Xu | Isolated heat-inducible cell surface protein and hyperthermia-based tumor immunotargeting therapy |
| US20070178458A1 (en) * | 2003-09-05 | 2007-08-02 | O'brien Philippa | Methods of diagnosis and prognosis of ovarian cancer II |
| WO2005026314A2 (fr) * | 2003-09-10 | 2005-03-24 | Japan Science And Technology Agency | Groupe de genes exprimes de facon differentielle dans des cellules de sang peripherique ainsi que procede de diagnostic et procede d'analyse mettant en oeuvre ce groupe |
| ES2346314T3 (es) * | 2003-10-02 | 2010-10-14 | Glaxosmithkline Biolog Sa | Antigenos de b. pertussis y uso de los mismos en vacunacion. |
| WO2005033144A2 (fr) | 2003-10-03 | 2005-04-14 | Brigham And Women's Hospital | Ligands de tim-3 et methodes associees |
| WO2005040791A2 (fr) * | 2003-10-21 | 2005-05-06 | Bayer Healthcare Ag | Diagnostics et therapeutiques pour maladies liees au recepteur de peptides similaire a la somatostatine et a l'angiogenine (salpr) |
| WO2005051994A2 (fr) * | 2003-11-21 | 2005-06-09 | Zymogenetics, Inc. | Facteur de necrose tumorale ztnf11 |
| ES2380340T3 (es) * | 2003-12-05 | 2012-05-10 | Northwestern University | Anfífilos peptídicos auto-ensamblantes y métodos relacionados para la administración de factores de crecimiento |
| ES2360113T3 (es) | 2003-12-23 | 2011-06-01 | Genomic Health, Inc. | Amplificación universal de rna fragmentado. |
| US20050186577A1 (en) | 2004-02-20 | 2005-08-25 | Yixin Wang | Breast cancer prognostics |
| DK1730303T3 (da) * | 2004-03-02 | 2013-11-04 | Univ Johns Hopkins | Mutationer i pik3ca-genet ved humane cancerformer |
| TW200539890A (en) | 2004-03-12 | 2005-12-16 | Brigham & Womens Hospital | Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
| WO2005090569A1 (fr) * | 2004-03-24 | 2005-09-29 | The Council Of The Queensland Institute Of Medical Research | Cancer et acides nucleiques et proteines de testicule vsm1 et vsm2, et leurs utilisations |
| NZ550542A (en) * | 2004-03-30 | 2009-03-31 | Nsgene As | Therapeutic use of a growth factor, NsG33 |
| ES2550614T3 (es) | 2004-04-09 | 2015-11-11 | Genomic Health, Inc. | Marcadores de expresión génica para predecir la respuesta a la quimioterapia |
| DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| WO2005118832A2 (fr) * | 2004-06-01 | 2005-12-15 | Bayer Healthcare Ag | Agents diagnostiques et therapeutiques pour des maladies associees a une proteine de type kinase regulee par serum/glucocorticoide (sgkl) |
| RS52593B (en) | 2004-06-24 | 2013-04-30 | Biogen Idec Ma Inc. | TREATMENT OF THE CONDITIONS CONCERNING DEMYELINIZATION |
| US7587279B2 (en) | 2004-07-06 | 2009-09-08 | Genomic Health | Method for quantitative PCR data analysis system (QDAS) |
| WO2006013661A1 (fr) * | 2004-08-05 | 2006-02-09 | Toagosei Co., Ltd. | Peptide déterminant antigénique anticorps de la maladie de crohn et reactif pour test de la maladie de crohn |
| ATE550440T1 (de) | 2004-11-05 | 2012-04-15 | Genomic Health Inc | Molekulare indikatoren für brustkrebsprognose und vorhersage des ansprechens auf eine behandlung |
| US7930104B2 (en) | 2004-11-05 | 2011-04-19 | Genomic Health, Inc. | Predicting response to chemotherapy using gene expression markers |
| CN102746404B (zh) | 2004-11-12 | 2016-01-20 | 赞科股份有限公司 | 对FcRn的结合被改变的Fc变体 |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| JP2008531733A (ja) | 2005-03-04 | 2008-08-14 | ノースウエスタン ユニバーシティ | 血管新生性のヘパリン結合エピトープ、ペプチド両親媒性物質、自己集合組成物、および関連する使用法 |
| EP1880005B1 (fr) * | 2005-05-13 | 2012-11-07 | Centre National de la Recherche Scientifique | Utilisation de nouveau codage genique pour nouvel element de la famille mcm2-8 dans les compositions pharmaceutiques |
| EP2394661A1 (fr) | 2005-07-08 | 2011-12-14 | Biogen Idec MA Inc. | Anticorps Sp35 et utilisations associées |
| WO2007014338A2 (fr) * | 2005-07-26 | 2007-02-01 | Siemens Medical Solutions Diagnostics | Polymorphismes de nucleotides uniques a susceptibilite par rapport a une maladie cardio-vasculaire |
| US8207128B2 (en) * | 2005-09-28 | 2012-06-26 | Supadelixir Inc. | Polypeptide inhibiting transmigration of leukocytes or growth and/or metastasis of cancer cells, and fusion protein thereof |
| EP1790664A1 (fr) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Anticorps monoclonaux contre claudin-18 pour le traitement du cancer |
| KR20090111307A (ko) * | 2006-07-03 | 2009-10-26 | 엑손히트 써라퓨틱스 에스에이 | 전립선 특이적 전사물 및 전립선암의 치료 및 진단에 사용되는 이의 용도 |
| CA2662915A1 (fr) * | 2006-09-08 | 2008-03-13 | Corixa Corporation | Procedes, compositions, et kits de detection et de surveillance d'un cancer du colon |
| US8076295B2 (en) | 2007-04-17 | 2011-12-13 | Nanotope, Inc. | Peptide amphiphiles having improved solubility and methods of using same |
| US8999634B2 (en) * | 2007-04-27 | 2015-04-07 | Quest Diagnostics Investments Incorporated | Nucleic acid detection combining amplification with fragmentation |
| GB0805159D0 (en) | 2008-03-19 | 2008-04-23 | Sancho Madrid David | Immune modulation via C-type lectin |
| HUE026776T2 (en) | 2007-07-27 | 2016-08-29 | Immatics Biotechnologies Gmbh | New immunogenic epitope for immunotherapy |
| US7863021B2 (en) | 2007-09-05 | 2011-01-04 | Celera Corporation | Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof |
| WO2009034661A1 (fr) * | 2007-09-12 | 2009-03-19 | Toppan Printing Co., Ltd. | Procédé de diagnostic et induction d'une résistance à un virus |
| ES2401233T3 (es) | 2007-10-17 | 2013-04-18 | Universidad de Córdoba | Isoformas del receptor tipo 5 de somatostatina humana producidas por tratamiento alternativo y pares de oligonucleótidos para la detección de las mismas por PCR |
| PL2235059T3 (pl) | 2007-12-26 | 2015-08-31 | Xencor Inc | Warianty FC o zmodyfikowanym wiązaniu do FCRN |
| GB0803352D0 (en) * | 2008-02-22 | 2008-04-02 | Ntnu Technology Transfer As | Oligopeptidic compounds and uses thereof |
| US9683031B2 (en) | 2008-03-21 | 2017-06-20 | Universiteit Hasselt | Biomarkers for rheumatoid arthritis |
| CA2997870A1 (fr) | 2008-07-09 | 2010-01-14 | Biogen Ma Inc. | Compositions renfermant des anticorps au lingo ou des fragments associes |
| US8334264B2 (en) | 2008-07-24 | 2012-12-18 | NsGenee A/S | Therapeutic use of a growth factor, METRNL |
| EP2172211B1 (fr) | 2008-10-01 | 2014-12-03 | Immatics Biotechnologies GmbH | Composition de peptide associé aux tumeurs et vaccin anti-cancer associé pour le traitement de glioblastome (GBM) et autres cancers |
| JP2012508586A (ja) | 2008-11-14 | 2012-04-12 | ジェン−プローブ・インコーポレーテッド | カンピロバクター属（Ｃａｍｐｙｌｏｂａｃｔｅｒ）核酸を検出するための組成物、キットおよび方法 |
| WO2010062960A2 (fr) | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | Méthodes de détermination d'une réceptivité à une thérapie par anti-tnfα lors d’une maladie intestinale inflammatoire |
| WO2010066018A1 (fr) * | 2008-12-09 | 2010-06-17 | Alethia Biotherapeutics Inc. | Nouveau variant rétroviral endogène humain d’erv3 et utilisations de celui-ci pour diagnostiquer le cancer des ovaires |
| JP2012523463A (ja) | 2009-04-13 | 2012-10-04 | ノースウエスタン ユニバーシティ | 軟骨再生のための新規なペプチドベースの足場およびその使用方法 |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| CA2787940C (fr) | 2010-01-27 | 2020-01-07 | Massachusetts Institute Of Technology | Agents polypeptidiques techniques pour la neutralisation de la grippe a large spectre ciblee |
| IL290591B2 (en) | 2010-09-29 | 2024-08-01 | Seagen Inc | Antibody drug preparations (ADC) that bind to 191P4D12 proteins |
| WO2012041328A1 (fr) | 2010-10-01 | 2012-04-05 | Nsgene A/S | Traitement de l'allodynie, de l'hyperalgésie, de la douleur spontanée et de la douleur illusionnelle |
| ES2677699T3 (es) * | 2010-12-14 | 2018-08-06 | Hananja Ehf | Actividad biológica de la proteína placentaria 13 |
| CN107596346A (zh) | 2011-09-05 | 2018-01-19 | 霍巴治疗公司 | 异常性疼痛、痛觉过敏、自发性疼痛、和幻痛的治疗 |
| AR088699A1 (es) * | 2011-11-09 | 2014-06-25 | Sanofi Sa | Diacilglicerol lipasa y usos de la misma |
| PT3489254T (pt) | 2012-04-30 | 2022-12-30 | Biocon Ltd | Proteínas de fusão direcionadas/imunomoduladoras e seus métodos de fabrico |
| WO2013167153A1 (fr) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Anticorps utiles dans le diagnostic du cancer |
| NZ702178A (en) | 2012-05-14 | 2017-01-27 | Biogen Ma Inc | Lingo-2 antagonists for treatment of conditions involving motor neurons |
| WO2013174404A1 (fr) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer |
| RU2678127C2 (ru) | 2012-11-13 | 2019-01-23 | Бионтех Аг | Агенты для лечения экспрессирующих клаудин раковых заболеваний |
| WO2014127785A1 (fr) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer |
| US9023353B2 (en) * | 2013-03-13 | 2015-05-05 | The Board Of Trustees Of The University Of Arkansas | Anti-(+)—methamphetamine monoclonal antibodies |
| WO2014146672A1 (fr) | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer |
| AU2014241162A1 (en) | 2013-03-27 | 2015-10-22 | Cedars-Sinai Medical Center | Mitigation and reversal of fibrosis and inflammation by inhibition of TL1A function and related signaling pathways |
| PL3019619T3 (pl) | 2013-07-11 | 2022-01-10 | Modernatx, Inc. | Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania |
| WO2015010108A1 (fr) | 2013-07-19 | 2015-01-22 | Cedars-Sinai Medical Center | Signature de la voie de signalisation de tl1a (tnfsf15) |
| US20150087810A1 (en) | 2013-09-25 | 2015-03-26 | Cytomx Therapeutics, Inc. | Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof |
| WO2015050158A1 (fr) * | 2013-10-01 | 2015-04-09 | 国立大学法人三重大学 | Vaccin d'induction de lymphocytes t contenant une séquence interépitope favorisant une présentation d'antigène |
| DK3628328T3 (da) | 2014-01-31 | 2022-12-05 | Cytomx Therapeutics Inc | Matriptase- og u-plasminogen-aktivatorsubstrater og andre spaltelige dele og fremgangsmåder til anvendelse deraf |
| JP2018504400A (ja) | 2015-01-08 | 2018-02-15 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用 |
| MA41374A (fr) | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| US11124766B2 (en) * | 2015-06-12 | 2021-09-21 | Emory University | Growth and survival compositions for cells capable of producing antibodies and methods related thereto |
| US10351869B2 (en) | 2015-09-04 | 2019-07-16 | Synthetic Genomics, Inc. | Microorganisms engineered for increased productivity |
| CN109462996A (zh) | 2016-03-17 | 2019-03-12 | 西达-赛奈医疗中心 | 通过rnaset2诊断炎性肠病的方法 |
| RU2018137981A (ru) * | 2016-03-29 | 2020-04-29 | Валкири Терапьютикс Инк. | Модуляция экспрессии структурной поддержки хромосомы-1 (smc1) |
| US9611297B1 (en) | 2016-08-26 | 2017-04-04 | Thrasos Therapeutics Inc. | Compositions and methods for the treatment of cast nephropathy and related conditions |
| US11125757B2 (en) | 2017-05-26 | 2021-09-21 | Emory University | Methods of culturing and characterizing antibody secreting cells |
| EP3508499A1 (fr) | 2018-01-08 | 2019-07-10 | iOmx Therapeutics AG | Anticorps ciblant et d'autres modulateurs d'un gène d'immunoglobuline associé à une résistance contre des réponses immunitaires antitumorales et leurs utilisations |
| JP2022512124A (ja) | 2018-12-06 | 2022-02-02 | シートムエックス セラピューティクス，インコーポレイテッド | マトリックスメタロプロテアーゼ切断可能なおよびセリンまたはシステインプロテアーゼ切断可能な基質ならびにそれらの使用方法 |
| KR20220012249A (ko) * | 2019-04-26 | 2022-02-03 | 상가모 테라퓨틱스, 인코포레이티드 | 조작 aav |
| EP3994171A1 (fr) | 2019-07-05 | 2022-05-11 | iOmx Therapeutics AG | Anticorps de liant à l'igc2 de l'igsf11 (vsig3) et leurs utilisations |
| WO2021083958A1 (fr) * | 2019-10-29 | 2021-05-06 | Specialites Pet Food | Nouveaux peptides induisant la satiété |
| WO2021194186A1 (fr) * | 2020-03-27 | 2021-09-30 | 원큐어젠 주식회사 | Composition comprenant un peptide vgll1 pour le traitement du cancer |
| WO2021228999A1 (fr) * | 2020-05-12 | 2021-11-18 | Institut Curie | Épitopes néo-antigéniques associés à des mutations sf3b1 |
| WO2022008027A1 (fr) | 2020-07-06 | 2022-01-13 | Iomx Therapeutics Ag | Anticorps de liaison à l'igv d'igsf11 (vsig3) et leurs utilisations |
| EP4281469A1 (fr) * | 2021-01-21 | 2023-11-29 | Erasmus University Rotterdam Medical Center | Lymphocytes t destinés à être utilisés en thérapie |
| US20220260597A1 (en) * | 2021-02-18 | 2022-08-18 | Beren Therapeutics P.B.C. | Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins |
| WO2023225602A1 (fr) * | 2022-05-20 | 2023-11-23 | Medikine, Inc. | Polypeptides de liaison au récepteur de l'interleukine-18 et leurs utilisations |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4446240A (en) * | 1981-01-30 | 1984-05-01 | Nerenberg Samuel T | Pancreas specific protein systems |
| US5457038A (en) * | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
| US6080540A (en) * | 1990-04-20 | 2000-06-27 | Cold Spring Harbor Laboratory | Cloning of mammalian genes in microbial organisms and methods for pharmacological screening |
| WO1992009617A1 (fr) * | 1990-11-26 | 1992-06-11 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Facteurs de transcription d'agression de cellules |
| US5721352A (en) * | 1991-02-19 | 1998-02-24 | University Of Florida Research Foundation | Entomopoxvirus expression system |
| US5840870A (en) * | 1995-12-29 | 1998-11-24 | Incyte Pharmaceuticals, Inc. | Polynucleotides PANC1A and PANC1B associated with pancreatic cancer |
| US5912160A (en) * | 1995-08-22 | 1999-06-15 | Thomas Jefferson University | Gab1, Grb2 binding protein, and compositions for making and methods of using the same |
| JP3462313B2 (ja) * | 1995-08-24 | 2003-11-05 | キッコーマン株式会社 | 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体ｄｎａ及び変異型ウリカーゼの製造法 |
| US5998165A (en) * | 1995-12-29 | 1999-12-07 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a protein associated with pancreatic cancer |
| WO1997040855A1 (fr) * | 1996-04-29 | 1997-11-06 | The Johns Hopkins University School Of Medicine | Regulateur de la degradation de l'arn chez les mammiferes induite par des transcrits non-sens |
| US6500934B1 (en) * | 1996-07-24 | 2002-12-31 | Michael Rush Lerner | Bivalent agonists for G-protein coupled receptors |
| US5976834A (en) * | 1997-01-09 | 1999-11-02 | Smithkline Beecham Corporation | cDNA clone HNFJD15 that encodes a novel human 7-transmembrane receptor |
| US5925521A (en) * | 1997-03-31 | 1999-07-20 | Incyte Pharmaceuticals, Inc. | Human serine carboxypeptidase |
| CA2232743A1 (fr) * | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | Tl5, homologue tnf |
| WO1998045435A2 (fr) * | 1997-04-10 | 1998-10-15 | Genetics Institute, Inc. | MARQUEURS SECRETES DE SEQUENCE EXPRIMEE (sEST) |
| IT1291110B1 (it) * | 1997-04-15 | 1998-12-29 | Istituto Europ Di Oncologia S | Interattori intracellulari e specificita' di legame del dominio eh |
| US5948641A (en) * | 1997-05-29 | 1999-09-07 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a metal response element binding protein |
| AU743490B2 (en) * | 1997-06-06 | 2002-01-24 | Regeneron Pharmaceuticals, Inc. | NTN-2 member of TNF ligand family |
| AU9484398A (en) * | 1997-09-17 | 1999-04-05 | Genentech Inc. | Promotion or inhibition of angiogenesis and cardiovascularization |
| US5932442A (en) * | 1997-09-23 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Human regulatory molecules |
| US5972660A (en) * | 1997-10-22 | 1999-10-26 | Incyte Pharmaceuticals, Inc. | Human hydroxypyruvate reductase |
| DE19818598A1 (de) * | 1998-04-19 | 1999-10-21 | Metagen Gesellschaft Fuer Genomforschung Mbh | Menschliche Nukleinsäuresequenzen aus Pankreasnormalgewebe |
| CN1158386C (zh) * | 1998-04-29 | 2004-07-21 | 吉尼西斯研究及发展有限公司 | 从皮肤细胞中分离的多核苷酸及其使用方法 |
| US6262249B1 (en) * | 1998-06-23 | 2001-07-17 | Chiron Corporation | Pancreatic cancer genes |
| CA2296792A1 (fr) * | 1999-02-26 | 2000-08-26 | Genset S.A. | Sequences marqueurs exprimees et proteines humaines codees |
-
2001
- 2001-01-17 WO PCT/US2001/001339 patent/WO2001055320A2/fr not_active Application Discontinuation
- 2001-01-17 WO PCT/US2001/001328 patent/WO2001055316A2/fr active Search and Examination
- 2001-01-17 AU AU2001241415A patent/AU2001241415A1/en not_active Abandoned
- 2001-01-17 CA CA002395827A patent/CA2395827A1/fr not_active Withdrawn
- 2001-01-17 CA CA002392450A patent/CA2392450A1/fr not_active Abandoned
- 2001-01-17 CA CA002395295A patent/CA2395295A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001336 patent/WO2001055204A1/fr active Search and Examination
- 2001-01-17 AU AU2001241416A patent/AU2001241416A1/en not_active Abandoned
- 2001-01-17 CA CA002393652A patent/CA2393652A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001308 patent/WO2001055364A2/fr active Search and Examination
- 2001-01-17 CA CA002395693A patent/CA2395693A1/fr active Pending
- 2001-01-17 CA CA002395849A patent/CA2395849A1/fr active Pending
- 2001-01-17 CA CA002395671A patent/CA2395671A1/fr not_active Withdrawn
- 2001-01-17 AU AU2001241408A patent/AU2001241408A1/en not_active Abandoned
- 2001-01-17 WO PCT/US2001/001342 patent/WO2001059064A2/fr active Search and Examination
- 2001-01-17 CA CA002392428A patent/CA2392428A1/fr not_active Abandoned
- 2001-01-17 CA CA002392422A patent/CA2392422A1/fr not_active Abandoned
- 2001-01-17 AU AU2001241413A patent/AU2001241413A1/en not_active Abandoned
- 2001-01-17 CA CA002393002A patent/CA2393002A1/fr not_active Withdrawn
- 2001-01-17 CA CA002395724A patent/CA2395724A1/fr active Pending
- 2001-01-17 WO PCT/US2001/001310 patent/WO2001055387A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001306 patent/WO2001055307A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001353 patent/WO2001055206A1/fr not_active Application Discontinuation
- 2001-01-17 WO PCT/US2001/001338 patent/WO2001055367A1/fr active Search and Examination
- 2001-01-17 CA CA002392398A patent/CA2392398A1/fr not_active Abandoned
- 2001-01-17 CA CA002397839A patent/CA2397839A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001351 patent/WO2001055355A1/fr active Search and Examination
- 2001-01-17 CA CA002395787A patent/CA2395787A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001333 patent/WO2001055448A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001314 patent/WO2001055310A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001344 patent/WO2001055324A2/fr active Search and Examination
- 2001-01-17 AU AU2001241405A patent/AU2001241405A1/en not_active Abandoned
- 2001-01-17 WO PCT/US2001/001309 patent/WO2001055308A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001239 patent/WO2001055301A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001317 patent/WO2001055201A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001356 patent/WO2001055173A2/fr not_active Application Discontinuation
- 2001-01-17 CA CA002394039A patent/CA2394039A1/fr not_active Abandoned
- 2001-01-17 CA CA002395654A patent/CA2395654A1/fr not_active Withdrawn
- 2001-01-17 AU AU2001241417A patent/AU2001241417A1/en not_active Abandoned
- 2001-01-17 CA CA002395178A patent/CA2395178A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001324 patent/WO2001055314A2/fr active Search and Examination
- 2001-01-17 AU AU2001241409A patent/AU2001241409A1/en not_active Abandoned
- 2001-01-17 CA CA002395734A patent/CA2395734A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001340 patent/WO2001055321A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001315 patent/WO2001055311A2/fr active Search and Examination
- 2001-01-17 CA CA002392438A patent/CA2392438A1/fr not_active Abandoned
- 2001-01-17 WO PCT/US2001/001352 patent/WO2001055327A2/fr not_active Application Discontinuation
- 2001-01-17 CA CA002395816A patent/CA2395816A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001345 patent/WO2001055325A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001330 patent/WO2001055447A1/fr active Search and Examination
- 2001-01-17 CA CA002395858A patent/CA2395858A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001335 patent/WO2001055319A2/fr active Search and Examination
- 2001-01-17 CA CA002398411A patent/CA2398411A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001348 patent/WO2001055368A1/fr active Search and Examination
- 2001-01-17 CA CA002395885A patent/CA2395885A1/fr not_active Withdrawn
- 2001-01-17 AU AU2001250770A patent/AU2001250770A1/en not_active Abandoned
- 2001-01-17 CA CA002398877A patent/CA2398877A1/fr not_active Withdrawn
- 2001-01-17 CA CA002393912A patent/CA2393912A1/fr not_active Withdrawn
- 2001-01-17 CA CA002395729A patent/CA2395729A1/fr active Pending
- 2001-01-17 CA CA002395403A patent/CA2395403A1/fr not_active Withdrawn
- 2001-01-17 AU AU2001241412A patent/AU2001241412A1/en not_active Abandoned
- 2001-01-17 WO PCT/US2001/001322 patent/WO2001055343A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001325 patent/WO2001055202A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001301 patent/WO2001055303A2/fr not_active Application Discontinuation
- 2001-01-17 AU AU2001241407A patent/AU2001241407A1/en not_active Abandoned
- 2001-01-17 CA CA002397407A patent/CA2397407A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001312 patent/WO2001054733A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001354 patent/WO2001057182A2/fr not_active Application Discontinuation
- 2001-01-17 CA CA002395699A patent/CA2395699A1/fr active Pending
- 2001-01-17 WO PCT/US2001/001327 patent/WO2001055203A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001358 patent/WO2001055163A1/fr not_active Application Discontinuation
- 2001-01-17 CA CA002394841A patent/CA2394841A1/fr not_active Withdrawn
- 2001-01-17 CA CA002395738A patent/CA2395738A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001313 patent/WO2001055200A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001316 patent/WO2001054473A2/fr active Search and Examination
- 2001-01-17 AU AU2001241418A patent/AU2001241418A1/en not_active Abandoned
- 2001-01-17 WO PCT/US2001/001240 patent/WO2001055302A2/fr not_active Application Discontinuation
- 2001-01-17 AU AU2001241406A patent/AU2001241406A1/en not_active Abandoned
- 2001-01-17 CA CA002395872A patent/CA2395872A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001321 patent/WO2001055312A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001311 patent/WO2001055309A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001357 patent/WO2001055208A1/fr not_active Application Discontinuation
- 2001-01-17 WO PCT/US2001/001355 patent/WO2001055207A1/fr not_active Application Discontinuation
- 2001-01-17 WO PCT/US2001/001350 patent/WO2001055350A1/fr active Search and Examination
- 2001-01-17 CA CA002395666A patent/CA2395666A1/fr not_active Withdrawn
- 2001-01-17 WO PCT/US2001/001359 patent/WO2001055328A2/fr active Application Filing
- 2001-01-17 WO PCT/US2001/001302 patent/WO2001055304A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001326 patent/WO2001055315A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001349 patent/WO2001054474A2/fr active Search and Examination
- 2001-01-17 CA CA002393618A patent/CA2393618A1/fr not_active Abandoned
- 2001-01-17 WO PCT/US2001/001343 patent/WO2001055323A2/fr active Search and Examination
- 2001-01-17 AU AU2001241410A patent/AU2001241410A1/en not_active Abandoned
- 2001-01-17 CA CA002395398A patent/CA2395398A1/fr not_active Withdrawn
- 2001-01-17 CA CA002392751A patent/CA2392751A1/fr not_active Abandoned
- 2001-01-17 AU AU2001241414A patent/AU2001241414A1/en not_active Abandoned
- 2001-01-17 WO PCT/US2001/001337 patent/WO2001055205A1/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001341 patent/WO2001055322A2/fr active Search and Examination
- 2001-01-17 WO PCT/US2001/001332 patent/WO2001055318A2/fr active Search and Examination
- 2001-01-17 CA CA002392757A patent/CA2392757A1/fr not_active Abandoned
- 2001-02-05 AU AU4313701A patent/AU4313701A/xx active Pending
- 2001-02-08 AU AU4141101A patent/AU4141101A/xx active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2395738A1 (fr) | Acides nucleiques, proteines et anticorps | |
| WO2001090304A2 (fr) | Acides nucleiques, proteines et anticorps | |
| WO2001055317A2 (fr) | Acides nucleiques, proteines et anticorps | |
| CA2395811A1 (fr) | Acides nucleiques, proteines, et anticorps | |
| WO2001055326A2 (fr) | Acides nucleiques, proteines et anticorps | |
| CA2395676A1 (fr) | Acides nucleiques, proteines et anticorps | |
| US20020151479A1 (en) | Nucleic acids, proteins, and antibodies | |
| EP1255766A2 (fr) | Acides nucleiques, proteines et anticorps | |
| CA2395889A1 (fr) | Acides nucleiques, proteines et anticorps | |
| CA2394022A1 (fr) | Acides nucleiques, proteines et anticorps | |
| CA2395857A1 (fr) | Acides nucleiques, proteines et anticorps | |
| CA2420320A1 (fr) | 7 proteines humaines secretees | |
| WO2002057420A2 (fr) | 50 proteines secretees humaines | |
| CA2392787A1 (fr) | Polynucleotides, polypeptides, et anticorps du recepteur de cellules nk | |
| WO2001055167A1 (fr) | Acides nucleiques, proteines et anticorps | |
| WO2001055162A1 (fr) | Acides nucleiques, proteines et anticorps | |
| EP1254217A2 (fr) | Acides nucl iques, prot ines et anticorps | |
| EP1261619A1 (fr) | Acides nucleiques, proteines et anticorps | |
| EP1261742A2 (fr) | Acides nucleiques, proteines et anticorps |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AZWI | Withdrawn application |